Stromal Protein-Mediated Immune Regulation in Digestive Cancers

Gamradt, Pia; Fouchardière, Christelle De La; Hennino, Anà

doi:10.3390/cancers13010146

Cited by 21 publications

(18 citation statements)

References 240 publications

(151 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, a few findings suggest that the NF-κB or ILK-RhoB pathways may be involved in integrin-mediated resistance (Monferran et al, 2008;Ahmed et al, 2013). The ECM proteoglycan, versican, can impact immune surveillance evasion along with hyaluronan by increasing the expression of inflammatory cytokines such as IL-6, TNFα, and NF-κB (Kang et al, 2017;Gordon-Weeks and Yuzhalin, 2020;Wight et al, 2020;Gamradt et al, 2021). Taken together, the complexity of the ECM in composition and structure as well as heterogeneity still needs to be further understood for therapeutic purposes.…”

Section: Extracellular Matrix (Ecm)mentioning

confidence: 99%

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment

Gao

et al. 2021

Front. Cell Dev. Biol.

112

View full text Add to dashboard Cite

Cancer is a disease which frequently has a poor prognosis. Although multiple therapeutic strategies have been developed for various cancers, including chemotherapy, radiotherapy, and immunotherapy, resistance to these treatments frequently impedes the clinical outcomes. Besides the active resistance driven by genetic and epigenetic alterations in tumor cells, the tumor microenvironment (TME) has also been reported to be a crucial regulator in tumorigenesis, progression, and resistance. Here, we propose that the adaptive mechanisms of tumor resistance are closely connected with the TME rather than depending on non-cell-autonomous changes in response to clinical treatment. Although the comprehensive understanding of adaptive mechanisms driven by the TME need further investigation to fully elucidate the mechanisms of tumor therapeutic resistance, many clinical treatments targeting the TME have been successful. In this review, we report on recent advances concerning the molecular events and important factors involved in the TME, particularly focusing on the contributions of the TME to adaptive resistance, and provide insights into potential therapeutic methods or translational medicine targeting the TME to overcome resistance to therapy in clinical treatment.

show abstract

Section: Extracellular Matrix (Ecm)mentioning

confidence: 99%

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment

Gao

et al. 2021

Front. Cell Dev. Biol.

112

View full text Add to dashboard Cite

show abstract

“…TME and stromal extracellular matrix (ECM) proteins can have a immune-modulatory functions, thus contributing to the immune evasion of cancer cells [119,120]. Immune surveillance is able to monitor, detect, and destroy cancer cells; however, as tumor progresses, cancer cells develop various mechanisms of immune evasion, leading to the development and the invasiveness of the tumor.…”

Section: Immunotherapy and Tme In Gastric Cancermentioning

confidence: 99%

“…Finally, although immunotherapy can result in long-lasting and major responses, a large portion of patients, however, do not benefit from this therapeutic approach, either from the beginning (i.e., primary resistance) or progressing after an initial response (i.e., acquired resistance). TAMs can limit the efficacy of immunotherapies, playing a tumor-supportive role; moreover, they can also reprogram MSCs to a state which is ideal for immunotherapy resistance in the tumor niche [120]. Interactions between MSCs and TAMs are complex and may represent a promising target for immunotherapy; however, the molecular and cellular mechanisms underlying these interactions have not been thoroughly identified and further evidence is still warranted.…”

Section: Immunotherapy and Tme In Gastric Cancermentioning

confidence: 99%

Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications

Rihawi

Ricci

Rizzo

et al. 2021

IJMS

114

View full text Add to dashboard Cite

Gastric cancer (GC) represents the fifth most frequently diagnosed cancer worldwide, with a poor prognosis in patients with advanced disease despite many improvements in systemic treatments in the last decade. In fact, GC has shown resistance to several treatment options, and thus, notable efforts have been focused on the research and identification of novel therapeutic targets in this setting. The tumor microenvironment (TME) has emerged as a potential therapeutic target in several malignancies including GC, due to its pivotal role in cancer progression and drug resistance. Therefore, several agents and therapeutic strategies targeting the TME are currently under assessment in both preclinical and clinical studies. The present study provides an overview of available evidence of the inflammatory TME in GC, highlighting different types of tumor-associated cells and implications for future therapeutic strategies.

show abstract

“…But transformed cancer cells can guide stromal cell reprogramming to support tumor growth and progression [ 26 ]. Furthermore, the stromal region has immunomodulatory functions, including blocking anti-tumor immunity, promoting immune escape and shaping immune cell population [ 27 , 28 ]. In recent years, anti-tumor stromal cell therapy is expected to become an important clinical therapeutic measure like targeting immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

Identification of prognostic biomarkers associated with tumor microenvironment in ceRNA network for esophageal squamous cell carcinoma: a bioinformatics study based on TCGA database

Song

Wei

et al. 2021

Discov Onc

View full text Add to dashboard Cite

Background Esophageal squamous cell carcinoma (ESCC) is the most common histological type of esophageal cancer in the world with high incidence rate and poor prognosis. Infiltrated immune and stromal cells are vital components of tumor microenvironment (TME) and have a significant impact on the progression of ESCC. The competitive endogenous RNA (ceRNA) hypothesis has been proved important in the molecular biological mechanisms of tumor development. However, there are few studies on the relationship between ceRNA and ESCC TME. Methods The proportion of tumor-infiltrating immune cells and the amount of stromal and immune cells in ESCC cases were calculated from The Cancer Genome Atlas database using the CIBERSORT and ESTIMATE calculation methods. After stratified identification of differentially expressed genes, WGCNA and miRNA prediction system were applied to construct ceRNA network. Finally, PPI network and survival analysis were selected to discriminate prognostic signature. And the results were verified in two independent groups from Gene Expression Omnibus and Lanzhou, China. Results We found that high Stromal and ESTIMATE scores were significantly associated with poor overall survival. Three TME-related key prognostic genes were screened, namely, LCP2, CD86, SLA. And the expression of them was significantly correlated with infiltrated immunocytes. It is also found that ESTIMATE Score and the expression of CD86 were both related to TNM system of ESCC. Conclusions We identified three novel TME-related prognostic markers and their lncRNA-miRNA-mRNA pathway in ESCC patients, which may provide new strategies for the targeted therapy.

show abstract

Stromal Protein-Mediated Immune Regulation in Digestive Cancers

Cited by 21 publications

References 240 publications

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment

Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications

Identification of prognostic biomarkers associated with tumor microenvironment in ceRNA network for esophageal squamous cell carcinoma: a bioinformatics study based on TCGA database

Contact Info

Product

Resources

About